Lilly adds $4.5 billion to Indiana sites that will make tirzepatide

Eli Lilly will put another $4.5 billion into its Lebanon, Indiana manufacturing campus, the company said on May 6, 2026, lifting its Indiana expansion commitments since 2020 past $21 billion and its total U.S. commitments past $50 billion ^[1][2][4].

The money is aimed at two of the three plants planned for the site: Lilly Lebanon API, an active pharmaceutical ingredient facility still under construction, and Lilly Lebanon Advanced Therapies, a genetic medicine factory that opened the same day ^[1][5]. Management said a growing pipeline and expected demand for the company's medicines drove the extra spending ^[1][4].

Tirzepatide is the molecule in Mounjaro, a type 2 diabetes injection for adults and children 10 and older, and in Zepbound, which is approved for weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity ^[1][4]. Lilly announced in 2024 that both would be produced in Lebanon; the new funding widens the site's planned output to include Foundayo (orforglipron), the company's once-daily weight loss pill, and retatrutide, an investigational triple hormone receptor agonist in late-stage trials for obesity and cardiometabolic disease ^[1][2][5].

"When our Lebanon API site opens in 2027, it will be the largest API production site in U.S. history, a commitment we chose to build here, at home," CEO David A. Ricks said in the announcement ^[1][4]. That plant is due to open in 2027 ^[1][5].

The campus covers 600 acres in the LEAP Research and Innovation District, roughly 28 miles northwest of Lilly's Indianapolis headquarters, and construction started in April 2023 ^[2]. Advanced Therapies is the first of the three to come online ^[1][5]. The third, the Lilly Medicine Foundry, is scheduled to finish in 2027 and is designed to combine research work with clinical-trial manufacturing of small molecules and biologics for cancer, diabetes and Alzheimer's disease ^[2].

Several details were not released: how the $4.5 billion is divided between the two buildings, how much production capacity the expansion adds, and how many jobs it creates ^[1][2][4]. The company also has not said whether the added output is expected to change U.S. supply or the prices patients pay for any of the medicines involved ^[1][2][4].

State and local governments have contributed money toward the Lebanon campus ^[2]. Lilly pointed to an Indiana University Kelley School of Business report due the following week that found the company accounts for 70% of Indiana's pharmaceutical GDP and that each of its jobs supports more than two others statewide; the company separately estimates that every dollar it spends in the area generates up to four dollars in additional local activity ^[1][2]. Lilly marked 150 years of Indiana operations in May 2026, according to the state commerce office ^[3].

Why it matters for patients

Tirzepatide is the active ingredient in Mounjaro and Zepbound, and Lebanon is the site Lilly says will make it. Anything that adds manufacturing capacity for that ingredient is relevant to how reliably those two products can be supplied, though the plant will not start operating until 2027 ^[1][5]. The expanded plans also cover Foundayo, an approved oral GLP-1, and retatrutide, which is not yet approved and is legally available only to participants in Lilly's clinical trials ^[1][4].

Nothing about the announcement changes what is in pharmacies today. There is no stated link between this spending and current availability of Mounjaro, Zepbound or Foundayo, and no pricing effect has been disclosed ^[1][2][4]. All three products remain prescription medicines, and Mounjaro is not indicated for weight loss ^[1].

What happens next

• Lilly Lebanon API is scheduled to open in 2027, and the Lilly Medicine Foundry is due for completion the same year ^[1][2][5].
• Lilly says it plans to break ground this year on several of its recently announced U.S. manufacturing sites ^[1][4], among them API plants in Virginia ($5 billion), Alabama ($6 billion) and Houston ($6.5 billion), plus a $3.5 billion injectables plant in Pennsylvania ^[2].
• The Kelley School of Business report on Lilly's Indiana contributions was due the week after the May 6 event; the company cited its findings ahead of publication ^[1].
• Industry-wide, drugmakers announced $370 billion in U.S. manufacturing pledges during 2025, a figure tracked by DPR Construction, as the Trump administration used tariff threats to push production onshore ^[2].